Literature DB >> 23704555

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Karthikeyan Veeraraghavalu1, Can Zhang, Sean Miller, Jasmin K Hefendehl, Tharinda W Rajapaksha, Jason Ulrich, Mathias Jucker, David M Holtzman, Rudolph E Tanzi, Robert Vassar, Sangram S Sisodia.   

Abstract

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23704555     DOI： 10.1126/science.1235505

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  76 in total

1.  Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases.

Authors:  Javier Riancho; Maria T Berciano; Jose Berciano; Miguel Lafarga
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 2.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 3.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

Review 4.  Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.

Authors:  Catherine Bowes Rickman; Sina Farsiu; Cynthia A Toth; Mikael Klingeborn
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-13       Impact factor: 4.799

5.  Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides.

Authors:  Jacques Fantini; Coralie Di Scala; Nouara Yahi; Jean-Denis Troadec; Kevin Sadelli; Henri Chahinian; Nicolas Garmy
Journal:  ACS Chem Neurosci       Date:  2014-01-12       Impact factor: 4.418

6.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

7.  Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.

Authors:  Valerie Bomben; Jerrah Holth; John Reed; Paige Cramer; Gary Landreth; Jeffrey Noebels
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

8.  Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.

Authors:  Xueli Zhang; Yanli Tian; Can Zhang; Xiaoyu Tian; Alana W Ross; Robert D Moir; Hongbin Sun; Rudolph E Tanzi; Anna Moore; Chongzhao Ran
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-21       Impact factor: 11.205

9.  ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.

Authors:  Angela W Corona; Nathan Kodoma; Brad T Casali; Gary E Landreth
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-15       Impact factor: 4.147

10.  High-density lipoprotein mimetic peptide 4F mitigates amyloid-β-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Suresh K Swaminathan; Karunya K Kandimalla; G William Rebeck; Ling Li
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.